3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow Granuloma Annulare: new trials by email Literature Review of Granuloma Annulare trials Research Report on Granuloma Annulare
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare AC-1101 - Granuloma Annulare | Phase 1 | Completed | TWi Biotechnology, Inc. | 13 | 2022-10-03 | 2024-10-15 |
| Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare Tofacitinib 5 mg twice daily - Cutaneous Sarcoidosis, Granuloma Annulare | Phase 1 | Completed | Yale University | 15 | 2019-04-11 | 2021-07-14 |
| Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix UVB Irradiation - Keloid, Scleroderma, Localized | Phase 1 / Phase 2 | Completed | University of Michigan | 33 | 2002-08-01 | 2015-05-01 |
Acne Keloid (1) · Cicatrix (1) · Keloid (1) · Scleroderma, Diffuse (1) · Scleroderma, Localized (1)
Collagen Diseases (3) · Connective Tissue Diseases (3) · Granuloma (3) · Necrobiotic Disorders (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Acneiform Eruptions (1) · Fibrosis (1) · Folliculitis (1) · Hair Diseases (1) · Scleroderma, Systemic (1)
tofacitinib (1)
TWi Biotechnology, Inc. (1) · University of Michigan (1) · Yale University (1)
United States (3)
John J Voorhees, MD (1) · William Damsky, M.D., Ph.D. (1) · William Damsky, MD, PhD (1)